| Literature DB >> 34268290 |
Jun-Jian Qin1, Yan-Fang Xing1, Jian-Hua Ren2, Yong-Jian Chen3, Ying-Fei Gan1, Yan-Qiu Jiang1, Jie Chen3, Xing Li3,4.
Abstract
Background: Infections are the second leading cause of death among patients undergoing hemodialysis. However, preventive measures against infectious diseases are limited and have not been made mandatory for patients. Objective: To investigate the incidence of infectious diseases before and during the coronavirus disease (COVID-19) pandemic. Design: A historical comparative study of a prospective cohort. Setting(s): February 1, 2015 to January 31, 2020 was defined as the period before the mitigative confrontation of the COVID-19 pandemic in China. The period from February 1 to June 29, 2020 was defined as the period of mitigative confrontation of the COVID-19 pandemic in China. Participants: A cohort of patients undergoing hemodialysis whose infectious disease episodes were documented prospectively in the hemodialysis unit of the Third Affiliated Hospital of Guangzhou Medical University since February 1, 2015.Entities:
Keywords: coronavirus disease 2019; hand hygiene; hemodialysis; infectious diseases; mask wearing; pneumonia
Year: 2021 PMID: 34268290 PMCID: PMC8277107 DOI: 10.3389/fpubh.2021.678738
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Hemodialysis patient characteristics before and during mitigative confrontation of the COVID-19 pandemic.
| Age (year, median, range) | 62 (24 – 92) | 60 (24 – 88) | 0.045 |
| Gender ( | 0.961 | ||
| Male | 84 (53.5) | 42 (53.2) | |
| Female | 73 (46.5) | 37 (46.8) | |
| End-stage renal disease cause ( | 0.681 | ||
| Polycystic kidney | 6 (3.8) | 4 (5.1) | |
| Hypertension | 19 (12.1) | 9 (11.4) | |
| Obstructive nephropathy | 7 (4.5) | 1 (1.3) | |
| Diabetes | 60 (38.2) | 33 (41.8) | |
| Transplant kidney failure | 5 (3.2) | 4 (5.1) | |
| Chronic nephritis syndrome | 57 (36.3) | 28 (35.4) | |
| Others | 3 (1.9) | 0 | |
| Body mass index (median, range) | 21.3 (13.3 – 44.4) | 21.6 (14.0 – 29.0) | 0.821 |
| Hypertension | 151 (96.2) | 77 (97.5) | 0.722 |
| Diabetes | 57 (36.3) | 32 (40.5) | 0.530 |
| Cardiovascular disease | 29 (18.5) | 15 (19.0) | 0.923 |
| Cerebrovascular disease | 38 (24.2) | 14 (17.7) | 0.257 |
| Obstructive nephropathy | 10 (6.4) | 3 (3.8) | 0.552 |
| Hemoglobin (g/L, mean ± S.D.) | 96.8 ± 17.2 | 101.0 ± 16.6 | 0.054 |
| Parathyroid hormone (μmol/L, median, range) | 436 (10 – 3,000) | 534 (10 – 3,000) | 0.262 |
| Serum calcium (mmol/L, mean ± S.D.) | 2.26 ± 0.21 | 2.31 ± 0.18 | 0.136 |
| Serum phosphorus (mmol/L, mean ± S.D.) | 2.12 ± 0.64 | 2.22 ± 0.65 | 0.289 |
| Creatinine (μmol/L, mean ± S.D.) | 965 ± 276 | 1,046 ± 239 | 0.027 |
| Systolic pressure (mmHg, median, range) | 140 (100 – 180) | 145 (112 – 180) | 0.152 |
| Diastolic pressure (mmHg, median, range) | 80 (57 – 130) | 83 (57 – 97) | 0.145 |
| Erythropoietin dosage (IU/week) ( | 0.174 | ||
| 4,000 | 27 (17.2) | 11 (13.9) | |
| 8,000 | 57 (36.3) | 40 (50.6) | |
| 12,000 | 73 (46.5) | 28 (35.4) | |
| Death | 49 (31.2) | 0 (0.0) | 0.000 |
| Length of Follow-up (month, median, range) | 39.5 (0.9 – 60.8) | 5 (5 – 5) | 0.000 |
| Length of Hemodialysis (month, median, range) | 52 (6 – 191) | 59.5 (6 – 191) | 0.430 |
Figure 1Patient flow diagram.
Adherence to infection prevention regulation of patients, caregivers, and HCWs in hemodialysis unit before and during mitigative confrontation of the COVID-19 pandemic.
| Hand sanitizer consumption (× 500 ml/season, median range) | 11 (10 – 18) | 22.5 (21 – 24) | 0.013 |
| Physicians | 66 (39 – 93) | 90.5 (87 – 94) | 0.052 |
| Nurses | 75.5 (67 – 86) | 92.5 (89 – 96) | 0.013 |
| Other employees | 55 (34 – 71) | 76.5 (72 – 81) | 0.013 |
| Mask-wearing rate of patients (incidence/observed individuals, %) | 3/194 (1.5) | 239/239 (100.0) | <0.001 |
HCWs, healthcare workers.
Figure 2Comparison on infectious episodes before and during the COVID-19 pandemic including (A) URTI, (B) pneumonia, (C) respiration infection, (D) catheter-related infection, (E) digestive tract infection, (F) other sites infection, (G) non-respiration infection, and (H) total infection. URTI, upper respiratory tract infection.
Comparison on infectious episodes before and during the COVID-19 pandemic.
| URTI | 0.1057 ± 0.1847 | 0.0356 ± 0.0954 | <0.001 |
| Pneumonia | 0.0538 ± 0.2735 | 0.0204 ± 0.0611 | <0.001 |
| Respiratory infection | 0.1585 ± 0.3956 | 0.0561 ± 0.1160 | <0.001 |
| Catheter-related infection | 0.0093 ± 0.0375 | 0.0025 ± 0.0226 | 0.003 |
| Digestive tract infection | 0.0085 ± 0.0460 | 0.0025 ± 0.0226 | 0.034 |
| Other sites of infection | 0.0133 ± 0.1320 | 0.0025 ± 0.0226 | 0.062 |
| Total infection | 0.1907 ± 0.4140 | 0.0637 ± 0.1230 | <0.001 |
URTI, upper respiratory tract infection.
Figure 3Historical paired comparison on infectious episodes before and during the COVID-19 pandemic. URTI, upper respiratory tract infection. *p < 0.05; **p < 0.01; ****p < 0.001.
Historical paired comparison on infectious episodes before and during the COVID-19 pandemic.
| URTI | 0.0595 ± 0.0932 | 0.0357 ± 0.0954 | <0.001 |
| Pneumonia | 0.0231 ± 0.0396 | 0.0204 ± 0.0611 | <0.001 |
| Respiratory infection | 0.0826 ± 0.1100 | 0.0561 ± 0.1160 | <0.001 |
| Catheter-related infection | 0.0164 ± 0.0511 | 0.0025 ± 0.0226 | <0.001 |
| Digestive tract infection | 0.0147 ± 0.0632 | 0.0025 ± 0.0226 | 0.006 |
| Other sites of infection | 0.0251 ± 0.1855 | 0.0025 ± 0.0226 | 0.006 |
| Total infection | 0.1388 ± 0.2219 | 0.0637 ± 0.1230 | <0.001 |
URTI, upper respiratory tract infection.